share_log

Intelligent Bio Solutions | UPLOAD: Others

Intelligent Bio Solutions | UPLOAD: Others

Intelligent Bio Solutions | UPLOAD:其他
美股sec公告 ·  03/13 13:08
Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 4, 2024, will not undergo review by the commission. The SEC's communication, dated March 13, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Benjamin Richie at the SEC is the point of contact for any further inquiries from the company.
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 4, 2024, will not undergo review by the commission. The SEC's communication, dated March 13, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Benjamin Richie at the SEC is the point of contact for any further inquiries from the company.
美國證券交易委員會(SEC)已通知在美國上市的Intelligent Bio Solutions Inc.,其於2024年3月4日提交的S-3表格註冊聲明將不接受該委員會的審查。美國證券交易委員會於2024年3月13日發給智能生物解決方案首席執行官哈里·西蒙尼迪斯的來文。美國證券交易委員會的信提醒該公司及其管理層,無論美國證券交易委員會的審查程序如何,他們都對披露的準確性和充分性負責。美國證券交易委員會還引用了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會的本傑明·裏奇是該公司任何進一步詢問的聯繫人。
美國證券交易委員會(SEC)已通知在美國上市的Intelligent Bio Solutions Inc.,其於2024年3月4日提交的S-3表格註冊聲明將不接受該委員會的審查。美國證券交易委員會於2024年3月13日發給智能生物解決方案首席執行官哈里·西蒙尼迪斯的來文。美國證券交易委員會的信提醒該公司及其管理層,無論美國證券交易委員會的審查程序如何,他們都對披露的準確性和充分性負責。美國證券交易委員會還引用了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會的本傑明·裏奇是該公司任何進一步詢問的聯繫人。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息